Pulse Biosciences, Inc · NASDAQ:PLSE
Pulse Biosciences — IPO Roadshow (April 2016)
27 slides from Pulse Biosciences's IPO roadshow presentation, Apr 19, 2016
Slide 1: Advancing therapies through cell signaling
Filed Registration April Advancing Darrin [Richard AprilPursuant 19, Uecker, 19, Nuccitelli, 2016 2016 therapies Statement to CEO/President ] Rule Ph.D., through 433 333-208694 CSOcell + signaling
Slide 2: Forward-Looking Statements
Wethe relates. and the This “expect,” statements. conduct Forward?looking of in Statement. In by Pulse research this companies prospectus have this presentation Biosciences Biosciences, forward?looking document, Before offering. future filed “intend,” The and These in aif clinical you Company develo
Slide 3: Pulse Biosciences Overview
Novelgenerator Addresses Proprietary Dominant Capital Pulse Potential PulPulse Biosciences therapeutic efficient Biosciences, strategic IP multiple position position platform commercialization tissue partnerships Confidential potential inwith Inc. nsPEF treatment being 339markets—Tissue granted tech
Slide 4: Unique Cellular Effect of Nanosecond Pulses
Pulsenanopores Nanosecond The Ca2+ PulPulse Biosciences increase Biosciences, pulses in allow aConfidential melanoma applied Ca2+ Inc. 4to across cell flow 4 Unique after ainto cellathe create single nsPEF cell,transient 100ns stressing Cellular pulse, nanopores Effect the shown endoplasmic inover t
Slide 5: Nano-Pulsed Electro-Signaling Modulating Apoptosis
Modulating Apoptosis This Nanosecond Cellular Ca2+ Response Immune Pulse Healing novel Biosciences Biosciences, Increase Apoptosis can non-thermal nanosecond Pulses leadConfidential Ablation Inc. to ablation, 5tissue pulsestreatment natural can 5 Nano-Pulsed induce healing, technology cellular Elect
Slide 6: Short treatment times with precise tissue ablation
Pulse We Short Healing An Current PulPulse ability believe treatment Biosciences treatment with Biosciences, toNPES induce little times—seconds technologies will Confidential orimmunogenic no Inc. deliver: scaring. 6 Precise that 6toNPES apoptosis, several burn and for orminutes. consistent Tissue f
Slide 7: Immune Response: Survival After Tumor Challenge
Survival N1-S1 Percent Days NPES 23 Chen 7Pulse Ratafter et Biosciences, Tx –Challenge treated liver Survival al. Immune Proportion Initial Euro tumors (n=23) JInjections Response of Inc. were (Immuno-protection) Cancer ablated, Data 50: 2705 seven (2014) weeks later secondary tumors were injected a
Slide 8: NPES Immune Response Data
NPESBiosciences, Tumor resisted 8Pulse –cells tumor Immune treated growth Response Inc. in vitro unlessData with theyNPES were were pre-treated used towith vaccinate an anti-CD8 mice against antibody. fibrosarcoma Nuccitelli et tumors. al. PLOS Three Oneweeks 10(7):e0134364 post vaccination 2015)ani
Slide 9: Tunable PulseTx System Design
PulsetoBiosciences Designed Plan Tunable PulseTxTM PulPulsesubmit design Biosciences, to System support ais510(k) based Confidential is Design adeveloping wide Inc. for on9asoft array novel 9tissue the PulseTxTM ofpulse first single ablation. tunable generator use–electrodes, The NPES architecture.
Slide 10: PulseTx Electrode Designs
Designs Cardiac rface Endoscopic Laparoscopic PulseTxTM Pulse 10 Electrodes Biosciences, Clamp for surface Electrode Electrodes is Electrode Electrode designed Inc. treatments Designs to support in open a broad surgery arrayand of minimally electrodes.invasive Relatively procedures. small incrementa
Slide 11: Pursuing Three Significant Vertical Markets
NPESBiosciences, Pursuing Published Tissue Veterinary Dermatology Oncology Pulse 11 Applications Ablation three data Medicine significant validates Inc. Oncology the vertical usemay ofmarkets: NPES represent inDermatology/Aesthetics, each an additional of these verticals. opportunity. Oncology, and
Slide 12: Dermatology/Aesthetics Vertical
Pulse Current NPES Short In Immune Example Seborrheic PulPulse office treatment Biosciences can treatments response treatment Biosciences, ofprovide Keratosis Single time potential Confidential athat NPES ofcompelling and freezing, Inc. will we Treatment 12 fit believe into burning 12 treatment Derm
Slide 13: Feasibility Demonstrated in Pilot Studies
Feasibility No NPES We May Example Wart Pulse 13 visible believe help Treatment Biosciences Biosciences, Wart Basal of understand scars demonstrated the this Pilot Wart BCC Cell study trial Example inStudy Treatment Carcinoma Treatment Confidential successfully Inc. will demonstrated thePilot demons
Slide 14: Planning Initial Dermatology Clinical Study
Pulse Planning Initial We PulPulse believe Biosciences regulatory Biosciences, forthe a clinical PulseTx clearance Confidential Inc. study will14 through be in dermatology 14 a good Dermatology/Aesthetics the fit straightforward in the in 2016 product to validate FDA portfolios – 510(k) Gotreatment
Slide 15: Oncology Vertical
Pulse Biosciences Cancer Checkpoint Leading PulseTxTM Potentially Note: PulPulse Pulse immunotherapy cancer Biosciences, overcomes synergistic inhibitors Biosciences platform centers Confidential may have Inc. with many are isisrevolutionizing play 15 not marketing shown other ofreceiving an 15 thei
Slide 16: Oncology: Immune Response Mechanisms
Oncology—Immune Oncolytic Intratumoral Virus Cell Tumor Adaptive NPES Cells CRT Dendritic Cytotoxic [Graphic Pulse 16 Lysis on undergo must Biosciences, Application In-Situ Antigen Cells surface Appears Immune Cell Viral T-cell (necrosis) enter injection Vaccine immunogenic Ingestion Immune Activati
Slide 17: Oncology: Demonstrate and Partner
Oncology Demonstrate -Partnership Pulse 17 The We Planning Several Biopharma believe first Biosciences, additional –clinical toopportunities Go there companies NPES execute to application market are Inc. provides applications aasmall number involved withlocal, study may medtech of may inoncology be
Slide 18: General Tissue Ablation: Partnership Strategy
General Engage -Partnership Additional Pulse 18 Potential Biosciences, strategic Tissue applications applications opportunities Ablation partners Inc. include in–inENT Partnership lung cardiac asthma, and ablation GI ablation Strategy specialties COPD, applications andmay chronic be pursued bronchit
Slide 19: Veterinary Medical Vertical
Commercial Veterinary -Medical *U.S. Pulse 19 It has there cancer 50% Existing No May Can regulatory Biosciences, de-bulk Pet of provide are been is Rationale all (Dog therapies over the dogs reported* Rationale tumor #1 a70 and clearance therapy simple cause will million Inc. tend Cat) with acquire
Slide 20: Veterinary Plan
Veterinary Plan Potentially Pulse 20 toBiosciences, execute engage –partner Golarge with studies to with Market Inc. high veterinary atlarge volume major veterinary chains veterinary veterinary todevice assess medicine oncologists or market oncology center(s) feasibility to perform companies to vali
Slide 21: Intellectual Property Patent Portfolio
Pulse We Patent 41 Current NPES Use PulPulse pending believe ofBiosciences pulse Portfolio NPES patents Biosciences, our worldwide generators, toNPES and 39 induce Confidential issued patent IP Inc. an electrodes, position worldwide immune applications 21 21enables Intellectual response and describe
Slide 22: Commercialization Strategy
Pulsefor Complete File Pilot Pursue PulPulse studies Biosciences partnerships and Biosciences, development obtain and partnering Confidential ain 510(k) Inc. applications of the 22 pre-510(k) clearance first 22 Commercialization tunable where ofclearance. the strategics NPES PulseTxTM platform, have
Slide 23: Experienced Management Team
PulsePresident Darrin COO Experience Rich Over Past Brian Dave PulPulse Nuccitelli, 120 Danitz, of Biosciences Dow, Uecker, Auxogyn, Biosciences, published in CFO VP Surgical of President/CEO Ph.D. the of Experienced Confidential CEO/President Engineering scientific Bioelectromagnetics Inc. –Robotic
Slide 24: Board of Directors
Pulse Biosciences Darrin Senior Co-Founder Thierry Former Mitch Founder Robert Co-managed PulPulse Levinson, Uecker, Managing Levande, Greenberg, Director CEO SVP Thaure, & Biosciences, Former of Accuray the Endogastric VirnetX President/CEO, Director Orthovita Alfred Director Chairman Director Conf
Slide 25: IPO Overview
Pulse 5,000,000 7.5 Pre-money Requirement Timing PulPulse million Biosciences ofBiosciences, offering shares valuation shares to raise atoutstanding Confidential –$4.00 early future approximately Inc.per May 25 capital share pre-offering, 25 IPO via $30rights Overview million; 12.5 offerings million
Slide 26: Investment Highlights
Pulse Broad Experienced A Capital Multiple PulPulse straightforward number Biosciences platform efficient value Biosciences, of team significant inflection technology value 510(k) capable Confidential Inc. creation applications milestones—clinical path of 26 with developing based plan; 26 a dominant
Slide 27: Pulse Biosciences Contact
[Pulse Advancing 849 Mitten Biosciences therapies Road Confidential + Suite through 104cell +27Burlingame, signaling California 94010 + Tel: 650.697.3939 ]